Pharmaceutical compositions for clinical nutrition
View Patent ↗The present disclosure relates to a pharmaceutical composition for providing phosphorus to an adult or pediatric patient, wherein the composition is an aqueous solution of sodium glycerophosphate which by virtue of an improved process for producing the active pharmaceutical ingredient and the pharmaceutical composition is characterized by a low amount of free phosphate, a low amount of SGP-related substances and by a low amount of aluminum. The pharmaceutical composition is used in clinical nutrition, preferably in the preparation of nutritional formulations by compounding. The compositions can further be used for preventing or correcting phosphorus deficiency (hyperphosphatemia) in said adult or pediatric patients.
1 . A pharmaceutical composition comprising sodium glycerophosphate (SGP) in a concentration of from about 0.5 mmol/mL to about 30.0 mmol/mL, wherein
(a) the amount of free phosphate is below 5% (w/w) of the total phosphate,
(b) the total amount of SGP related substances is below 15% (w/w) of the total phosphate, and
(c) the amount of aluminum is below 500 ppb.
2 . The pharmaceutical composition according to claim 1 , wherein the ratio of alpha sodium glycerophosphate (α-SGP) and beta sodium glycerophosphate (β-SGP) is from about 1:5 to about 5:1.
3 . The pharmaceutical composition according to claim 1 , wherein the pH is from about 5.0 to about 8.0.
4 . The pharmaceutical composition according to claim 1 , wherein the composition is provided in a polymeric container.
5 . The pharmaceutical composition according to claim 1 , wherein the composition is terminally heat-sterilized.
6 . The pharmaceutical composition according to claim 1 , wherein the SGP related substances in the pharmaceutical composition are selected from the group consisting of glycerodiphosphate (GDP), diglycerophosphate (DGP), triglycerophosphate (TGP), diglycerodiphosphate (DGDP), triglycerodiphosphate (TGDP), cyclic glycerodiphosphate (CGDP), and diglycerotriphosphate (DGTP).
7 . The pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition is stable at a temperature of from about 1° C. to about 25° C. for at least 12 months.
8 . The pharmaceutical composition according to claim 1 for the administration of phosphate to a patient.
9 . The pharmaceutical composition according to claim 1 for prevention or treatment of phosphate deficiency in a patient.
10 . The pharmaceutical composition according to claim 8 , wherein the patient is a patient receiving parenteral nutrition.
11 . The pharmaceutical composition according to claim 1 , wherein the patient is an adult or a pediatric patient.
12 . The pharmaceutical composition according to claim 1 for use in the compounding of a parenteral nutrition formulation.
13 . The pharmaceutical composition according to claim 1 for addition to a ready-to-use parenteral nutrition product or a solution for intravenous injection.
14 . A method of preparing a pharmaceutical composition according to claim 1 comprising the steps of:
(a) Dissolving an SGP drug product in water to form a SGP solution for injection under pH control;
(b) Adjusting the pH of the SGP solution to a value of from about 6.8 to about 7.8, preferably with hydrochloric acid;
(c) Filling the SGP solution into a polymeric container;
(d) Overpouching the filled and sealed container; and
(e) Sterilizing SGP solution in the container before or after step (d);
wherein the SGP drug product used comprises not more than 500 pbb of aluminum, not more than 15% (w/w) of SGP related substances and not more than 5% (w/w) of free phosphate.
15 . A method of preparing a sodium glycerophosphate drug product for use in the production of a pharmaceutical composition according to claim 1 comprising the steps of:
(a) reacting a mixture of phosphoric acid and sodium phosphate, preferably at a ratio of about 20:80, with glycerol at a temperature of from about 130° C. to about 150° C. to form a reaction mixture;
(b) distilling off water which is generated during the reaction from the reaction mixture;
(c) saponifying, preferably at a pH of between about 12 and about 13, and maintaining the reaction mixture at about 90° C. to 110° C. for about 2 to 5 hours;
(d) crystallizing the sodium glycerophosphate by precipitation from a solution of the reaction mixture comprising the sodium glycerophosphate in water and ethanol; and optionally
(e) drying the sodium glycerophosphate.
16 . The method according to claim 15 , wherein the reaction of step (a) is done with monobasic sodium phosphate and wherein glycerol is added at 3 to 6eq.
17 . The method according to claim 15 , wherein the saponification of step (c) is done with sodium hydroxide, preferably with about 0.3 to about 0.4 equivalents.
18 . The method according to claim 15 , wherein the crystallization of step (d) is performed at a temperature of from about 1° C. to about 20° C.
19 . A sodium glycerophosphate (SGP) drug product, wherein the SGP drug product is produced according to claim 15 , and the total amount of SGP related substances is below 15% (w/w) of the total phosphate in the SGP drug product.
20 . A sodium glycerophosphate (SGP) drug product, wherein
(a) the amount of free phosphate in the drug product is not more than 5% (w/w) of the total phosphate,
(b) the total amount of SGP-related substances in the drug product is not more than 15% (w/w) of the total phosphate, and
(c) the amount of aluminum in the drug product is not more than 500 ppb.
21 . The pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition is stable at a temperature of from about 1° C. to about 25° C. for at least 18 months.
22 . The pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition is stable at a temperature of from about 1° C. to about 25° C. for at least 24 months.
23 . The pharmaceutical composition according to claim 1 , wherein the amount of aluminum is below 250 ppb.
24 . The pharmaceutical composition according to claim 1 , wherein the amount of SGP related substances is below 12% (w/w) of the total phosphate.
25 . The SGP drug product according to claim 19 , wherein the SGP related substances are selected from the group consisting of glycerodiphosphate (GDP), diglycerophosphate (DGP), triglycerophosphate (TGP), diglycerodiphosphate (DGDP), triglycerodiphosphate (TGDP), cyclic glycerodiphosphate (CGDP), and diglycerotriphosphate (DGTP).
26 . The SGP drug product according to claim 20 , wherein the SGP related substances are selected from the group consisting of glycerodiphosphate (GDP), diglycerophosphate (DGP), triglycerophosphate (TGP), diglycerodiphosphate (DGDP), triglycerodiphosphate (TGDP), cyclic glycerodiphosphate (CGDP), and diglycerotriphosphate (DGTP).
27 . The SGP drug product according to claim 20 , wherein the ratio of alpha sodium glycerophosphate (α-SGP) and beta sodium glycerophosphate (β-SGP) is from about 1:5 to about 5:1.